CHICAGO--(BUSINESS WIRE)--CytoCore Inc. (OTCBB:CYOE), the developer of cost-effective, highly accurate screening systems for early detection of gynecological cancers and sexually transmitted diseases, today announced that it has received the report of the Interim Analysis that was performed on the data from its clinical trial on Adequacy, Efficacy and Safety between the SoftPAP® Collector Compared to Standard Spatula/CytoBrush Technique (NCT00474968). The Interim Analysis included data from approximately 300 patients of the 650 patient trial. Based on the data reviewed in the Interim Analysis, statistically significant differences between the SoftPAP® Collector and the Standard Spatula/CytoBrush Technique are noted in the report. CytoCore considers the trends shown in this report to be promising.
